Skip Navigation


NDT Advance Access originally published online on March 29, 2005
Nephrology Dialysis Transplantation 2005 20(6):1057-1065; doi:10.1093/ndt/gfh705
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/6/1057    most recent
gfh705v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lee, S.
Right arrow Articles by Park, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S.
Right arrow Articles by Park, S. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Original Article

Agonist of peroxisome proliferator-activated receptor-{gamma}, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model

Sik Lee1, Won Kim1, Kyung Pyo Kang1, Sang-ok Moon1, Mi Jeong Sung1, Duk Hoon Kim1, Hyung Jin Kim2 and Sung Kwang Park1

1 Department of Internal Medicine and 2 Urology, Renal Regeneration Laboratory, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, South Korea

Correspondence and offprint requests to: Sung Kwang Park, MD, Department of Internal Medicine, Chonbuk National University Medical School, 634-18, Keum-Am Dong, Jeonju, 561-712, South Korea. Email: kidney{at}chonbuk.ac.kr

Background. Agonists of the peroxisome proliferator-activated receptor-{gamma} may help to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules. The purpose of this study was to determine the protective effects of rosiglitazone on renal injury in a sepsis model and to explore the mechanism.

Methods. In lipopolysaccharide (LPS)-induced mouse sepsis, we examined the effect of rosiglitazone on LPS-induced overproduction of inflammatory mediators, on the expression of adhesion molecules in renal tubular epithelial cells and on renal function. The mechanism of the protective effect was investigated in vitro using human renal tubular epithelial cells.

Results. Rosiglitazone significantly decreased serum tumour necrosis factor (TNF)-{alpha} and interleukin (IL)-1ß levels during sepsis. The levels of blood urea nitrogen and creatinine were significantly lower in mice pre-treated with rosiglitazone than that in LPS-treated mice. Rosiglitazone reduced the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in tubular epithelial cells and interstitium of LPS-treated mice. Pre-treatment with rosiglitazone reduced the infiltration of macrophages/monocytes in renal tissue. In cultured tubular epithelial cells, rosiglitazone significantly decreased the expression of ICAM-1 and VCAM-1 induced by TNF-{alpha} or IL-1ß, inhibited the degradation of inhibitor {kappa}B{alpha} (I{kappa}B{alpha}) and blocked the activation of the p65 subunit of nuclear factor (NF)-{kappa}B.

Conclusions. These results indicate that pre-treatment with rosiglitazone attenuated the production of TNF-{alpha} and IL-1ß and reduced adhesion molecule expression in renal tubular epithelial cells of LPS-treated mice. Rosiglitazone has an anti-inflammatory effect in renal tubular epithelial cells through the inhibition of NF-{kappa}B activation.

Keywords: adhesion molecules; renal tubular epithelial cells; rosiglitazone; sepsis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Innate ImmunityHome page
Yulan Liu, Junxia Shi, Jing Lu, Guoquan Meng, Huiling Zhu, Yongqing Hou, Yulong Yin, Shengjun Zhao, and Binying Ding
Activation of peroxisome proliferator-activated receptor-{gamma} potentiates pro-inflammatory cytokine production, and adrenal and somatotropic changes of weaned pigs after Escherichia coli lipopolysaccharide challenge
Innate Immunity, June 1, 2009; 15(3): 169 - 178.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. J. Ko, Y. S. Kang, S. Y. Han, M. H. Lee, H. K. Song, K. H. Han, H. K. Kim, J. Y. Han, and D. R. Cha
Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2750 - 2760.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Boulanger, R. Mansouri, J. F. Gautier, and D. Glotz
Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?
Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2696 - 2702.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Lee, S.-O. Moon, W. Kim, M. J. Sung, D. H. Kim, K. P. Kang, Y. B. Jang, J. E. Lee, K. Y. Jang, S. Y. Lee, et al.
Protective role of L-2-oxothiazolidine-4-carboxylic acid in cisplatin-induced renal injury
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2085 - 2095.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Lee, W. Kim, S.-O. Moon, M. J. Sung, D. H. Kim, K. P. Kang, Y. B. Jang, J. E. Lee, K. Y. Jang, and S. K. Park
Rosiglitazone ameliorates cisplatin-induced renal injury in mice
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2096 - 2105.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. C.W. Tang, J. C.K. Leung, L. Y.Y. Chan, A. W.L. Tsang, and K. N. Lai
Activation of Tubular Epithelial Cells in Diabetic Nephropathy and the Role of the Peroxisome Proliferator-Activated Receptor-{gamma} Agonist
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1633 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
P. Iglesias and J. J Diez
Peroxisome proliferator-activated receptor gamma agonists in renal disease.
Eur. J. Endocrinol., May 1, 2006; 154(5): 613 - 621.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.